Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Harmony Biosciences Holdings (HRMY) EBITDA Margin (2020 - 2025)

Harmony Biosciences Holdings' EBITDA Margin history spans 6 years, with the latest figure at 9.22% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 1515.0% year-over-year to 9.22%; the TTM value through Dec 2025 reached 18.3%, down 206.0%, while the annual FY2025 figure was 18.3%, 206.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 9.22% at Harmony Biosciences Holdings, down from 21.29% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 74.91% in Q3 2022 and bottomed at 11.92% in Q3 2021.
  • The 5-year median for EBITDA Margin is 24.52% (2024), against an average of 23.75%.
  • The largest annual shift saw EBITDA Margin surged 8682bps in 2022 before it plummeted -5090bps in 2023.
  • A 5-year view of EBITDA Margin shows it stood at 24.9% in 2021, then skyrocketed by 52bps to 37.83% in 2022, then crashed by -57bps to 16.11% in 2023, then surged by 51bps to 24.37% in 2024, then tumbled by -62bps to 9.22% in 2025.
  • Per Business Quant, the three most recent readings for HRMY's EBITDA Margin are 9.22% (Q4 2025), 21.29% (Q3 2025), and 19.84% (Q2 2025).